Pregled bibliografske jedinice broj: 1215528
Re: Xiao et al.: Randomized controlled trial of a dichoptic digital therapeutic for amblyopia (Ophthalmology. 2022;129:77–85)
Re: Xiao et al.: Randomized controlled trial of a dichoptic digital therapeutic for amblyopia (Ophthalmology. 2022;129:77–85) // Ophthalmology, 129 (2022), 10; e151-e152 doi:10.1016/j.ophtha.2022.06.015 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1215528 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Re: Xiao et al.: Randomized controlled trial of a
dichoptic digital
therapeutic for amblyopia (Ophthalmology.
2022;129:77–85)
(Re: Xiao et al.: Randomized controlled trial of a
dichoptic digital
therapeutic for amblyopia (Ophthalmology.
2022;129:77–85))
Autori
Bjeloš, Mirjana ; Sonicki, Zdenko ; Bušić, Mladen ; Ćurić, Ana ; Elabjer, Biljana Kuzmanović
Izvornik
Ophthalmology (0161-6420) 129
(2022), 10;
E151-e152
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Ophthalmology ; Amblyopia ; Therapeutics
Sažetak
To The Editor: Xiao et al1 defined a clinically significant vision improvement associated with the use of a digital therapeutic for the treatment of amblyopia from anisometropia, strabismus, or both. The primary outcome was set as the difference in visual acuity (VA) of 0.75 lines. Visual acuity improvement from the therapeutic plus glasses over continued glasses alone was 1 line over 12 weeks. The benefit might be highly important because currently none of the alternative therapeutic modalities have supplanted occlusion. Stereoacuity was not improved.
Izvorni jezik
Engleski
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
